文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者预防性血小板输注反应:一项前瞻性多中心观察性研究

Prophylactic platelet transfusion response in critically ill patients: a prospective multicentre observational study.
PubMed 文献 · Crit Care · 2023-09-27
一句话结论重症患者中近四分之三的预防性血小板输注在18-24小时未达次优血小板增量,血小板保存时间是唯一可干预的相关因素。

这项前瞻性多中心观察性研究在9个ICU招募了至少接受一次预防性血小板输注的患者,最长观察16个月。次优血小板输注反应定义为输注后18-24小时校正计数增量(CCI)小于7。472次预防性输注中349次(73.9%)出现次优反应,181例患者中141例(77.9%)出现。混合效应模型显示,ICU入院时血红蛋白(OR 0.79 [95%CI 0.7-0.89])和BMI(OR 0.93 [0.89-0.98])与输注反应正相关,而血液系统恶性肿瘤(OR 1.93 [1.09-3.43])、以脓毒症为主要ICU入院诊断(OR 2.81 [1.57-5.03])、SOFA评分(OR 1.10 [1.03; 1.17])和血小板最长保存时间(OR 1.24 [1.02-1.52])与次优血小板增量独立相关。临床结局和红细胞需求在两组间无差异。血液系统恶性肿瘤接受化疗的患者中93.5%出现次优反应。作者认为血小板保存时间是唯一可能可干预的相关因素。

要点

  • 预防性血小板输注后18-24小时CCI<7定义为次优反应,472次输注中349次(73.9%)出现,181例患者中141例(77.9%)出现。
  • 以脓毒症为主要ICU入院诊断与次优血小板增量独立相关(OR 2.81 [95%CI 1.57-5.03]),SOFA评分每升高1分OR 1.10 [1.03; 1.17]。
  • 血液系统恶性肿瘤(OR 1.93 [1.09-3.43])和血小板最长保存时间(OR 1.24 [1.02-1.52])与次优反应独立相关。
  • ICU入院时血红蛋白(OR 0.79 [95%CI 0.7-0.89])和BMI(OR 0.93 [0.89-0.98])与较好的血小板输注反应独立相关。
  • 血液系统恶性肿瘤接受化疗的患者中93.5%出现次优血小板输注反应;临床结局和红细胞需求在反应组与次优反应组间无差异。

适用人群与场景

  • 在9个参与ICU中接受至少一次预防性血小板输注的成人重症患者,观察期最长16个月。
  • 敏感性分析分别纳入和不纳入血液系统恶性肿瘤及化疗患者。

诊断标准与关键阈值

  • 次优血小板输注反应定义为校正计数增量(CCI,校正血小板剂量和体表面积)在血小板输注后18-24小时小于7。

研究设计与关键结果

  • 前瞻性多中心观察性研究,9个ICU参与,472次预防性血小板输注中349次(73.9%)出现次优反应,181例患者中141例(77.9%)出现。
  • 混合效应模型:ICU入院时血红蛋白(OR 0.79 [95%CI 0.7-0.89])和BMI(OR 0.93 [0.89-0.98])与血小板输注反应正相关;血液系统恶性肿瘤(OR 1.93 [1.09-3.43])、以脓毒症为主要ICU入院诊断(OR 2.81 [1.57-5.03])、SOFA评分(OR 1.10 [1.03; 1.17])和血小板最长保存时间(OR 1.24 [1.02-1.52])与次优血小板增量独立相关。
  • 临床结局在组间无差异,红细胞需求也无差异。
  • 血液系统恶性肿瘤接受化疗的患者中93.5%出现次优血小板输注反应。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性研究。
  • 试验注册:ClinicalTrials.gov NCT03325140,注册于2017年10月。
  • 作者结论:血小板保存时间是唯一与次优血小板反应相关且可能可干预的因素。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在重症患者中,尤其是以脓毒症为主要入院诊断、SOFA评分较高、合并血液系统恶性肿瘤或接受化疗者,预防性血小板输注后18-24小时CCI常不达标,作者认为血小板保存时间是唯一可能可干预的相关因素。
  • 该研究显示次优血小板输注反应组与反应组临床结局无差异,红细胞需求也无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Response to prophylactic platelet transfusion is suspected to be inconsistent in critically ill patients questioning how to optimize transfusion practices. This study aimed to describe prophylactic platelet transfusion response, to identify factors associated with a suboptimal response, to analyse the correlation between corrected count increment and platelet count increment and to determine the association between poor platelet transfusion response and clinical outcomes.

METHODS: This prospective multicentre observational study recruited patients who received at least one prophylactic platelet transfusion in one of the nine participating intensive care units for a period up to 16 months. Poor platelet transfusion response was defined as a corrected count increment (CCI) that adjusts for platelet dose and body surface area, less than 7 at 18-24 h after platelet transfusion. Factors associated with poor platelet transfusion response were assessed in a mixed-effect model. Sensitivity analyses were conducted in patients with and without haematology malignancy and chemotherapy.

RESULTS: Poor platelet transfusion response occurred in 349 of the 472 (73.9%) prophylactic platelet transfusions and in 141/181 (77.9%) patients. The mixed-effect model identified haemoglobin at ICU admission (odds ratio (OR): 0.79 [95% confidence interval (CI) 0.7-0.89]) and body mass index (BMI) (OR: 0.93 [0.89-0.98]) being positively and independently associated with platelet transfusion response, while a haematological malignancy (OR 1.93 [1.09-3.43]), sepsis as primary ICU admission diagnosis (OR: 2.81 [1.57-5.03]), SOFA score (OR 1.10 [1.03; 1.17]) and maximum storage duration of platelet (OR: 1.24 [1.02-1.52]) were independently associated with a suboptimal platelet increment. Clinical outcomes did not differ between groups, nor the requirement for red blood cells. Poor platelet transfusion response was found in 93.5% of patients with haematology malignancy and chemotherapy.

CONCLUSIONS: In this study of critically ill patients, of whom more than half had bone marrow failure, almost three quarters of prophylactic platelet transfusions led to suboptimal platelet increment measured 18 to 24 h following platelet transfusion. Platelet storage duration was the only factor associated with poor platelet response that may be accessible to intervention. Trial registration in October 2017: ClinicalTrials.gov: NCT03325140.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reizine F, Le Marec S, Le Meur A, et al. Prophylactic platelet transfusion response in critically ill patients: a prospective multicentre observational study. Crit Care. 2023. PMID: 37759268. doi:10.1186/s13054-023-04650-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。